SEC Form 5 · accession 0000899243-19-003657
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lesley Ann Calhoun
Officer — See Remarks
Period of report
Dec 31, 2018
Accepted (ET)
Feb 14, 2019 · 5:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 31, 2018 | A | 510 | $21.34 | A | 1,987 | D | |
| Common Stock | Mar 15, 2018 | S | 510 | $54.68 | D | 1,477 | D | |
| Common Stock | Jul 3, 2018 | S | 187 | $44.88 | D | 1,290 | D | |
| Common Stock | Aug 1, 2018 | S | 258 | $43.52 | D | 1,032 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Remarks
Vice President, Finance and Principal Accounting Officer